RecruitingNot ApplicableNCT07407231

Combined Chemotherapy And Ablative Radiotherapy (SBRT) As First-Line Treatment In Locally Advanced Inoperable Pancreatic Cancer (SBRT-PANC)

Efficacy Of Combination Chemotherapy And Ablative Radiotherapy (SBRT) In The First-Line Treatment Of Locally Advanced Inoperable Pancreatic Cancer

Sponsor

Institute of Oncology Ljubljana

Enrollment

18 participants

Start Date

Sep 1, 2021

Study Type

INTERVENTIONAL

Conditions

Locally Advanced Pancreatic Cancer

Summary

This prospective interventional clinical study evaluates the efficacy and safety of combining systemic chemotherapy followed by ablative stereotactic body radiotherapy (SBRT) as first-line treatment in adult patients with locally advanced, inoperable pancreatic cancer. The study aims to determine the response rate after SBRT delivered following initial chemotherapy, as well as time to disease progression and treatment-related toxicity. Patients receive standard first-line chemotherapy and, in the absence of disease progression, undergo ablative SBRT to the primary tumor, followed by continuation of systemic therapy according to clinical practice. The study is conducted in Slovenia, with patient enrollment expanded to additional participating clinical centers following an approved amendment.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether combining chemotherapy with a focused, high-dose radiation treatment called SBRT (stereotactic body radiotherapy) works well as a first treatment for pancreatic cancer that has not spread but cannot be removed with surgery. **You may be eligible if...** - You are 18 or older - You have locally advanced pancreatic cancer that cannot be surgically removed - You are receiving first-line chemotherapy followed by SBRT at a participating center - You are able to give written consent **You may NOT be eligible if...** - Your pancreatic cancer has already spread to other parts of the body (metastatic) - You have already received prior chemotherapy or other systemic treatment for this cancer - Your cancer got worse during chemotherapy before starting radiation - You have a health condition that would interfere with study participation Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONAblative Stereotactic Body Radiotherapy (SBRT)

Ablative stereotactic body radiotherapy (SBRT) delivered to the primary pancreatic tumor after initial chemotherapy in patients without disease progression.

DRUGStandard First-Line Chemotherapy

Standard first-line systemic chemotherapy administered according to institutional guidelines (e.g., modified FOLFIRINOX or gemcitabine plus nab-paclitaxel), followed by continuation of systemic therapy after SBRT as clinically indicated.

Locations(1)

Institute of Oncology Ljubljana

Ljubljana, Slovenia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07407231

Related Trials

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

NCT036822893 locations

Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC)

NCT036524282 locations

Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC

NCT0325703342 locations

MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial

NCT059755931 location

Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer

NCT042768572 locations